Health Trials

AML, Adult Recurrent

4

Review clinical trials related to AML, Adult Recurrent. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your cancer.

Participants needed: 19
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: BlueSphere Bio, IncUpdated: May 5, 2026Locations: 1
Eligibility criteria

Male or female patients, ages 18 years or older, [+8]

Leukemic blast count of >20,000/μl. If the blast count can be maintained below t... [+21]

Read more
Status: Recruiting

BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

The goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS). It will evaluate the safety of BSB-1001 and also determine whether it works to prevent relapse of your cancer.

Participants needed: 38
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: BlueSphere Bio, IncUpdated: Sep 18, 2025Locations: 6
Eligibility criteria

Male or female patients, ages 18 - 70 years inclusive, undergoing alloHCT. [+7]

Weight > 100 kg. [+10]

Read more
Status: Recruiting

Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML

This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD33 or CD123 or both sequentially in the treatment of Acute Myelocytic Leukemia.

Participants needed: 85
Trial details
Phase: Phase 1, Phase 2Age: 6-90Biological sex: AllType: InterventionalSponsor: Essen BiotechUpdated: Nov 12, 2024Locations: 1
Eligibility criteria

Age older than 6 months. [+6]

Severe illness or medical condition, which would not permit the patient to be ma... [+5]

Read more
Status: Recruiting

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

This Trial is an open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with AML and NHL who previously received standard treatment or are ineligible for standard treatment options.

Participants needed: 60
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Shengke Pharmaceuticals (Jiangsu) Limited, ChinaUpdated: May 8, 2024Locations: 2
Eligibility criteria

Be at least 18 years of age and < 80 years old. [+26]

Acute promyelocytic leukemia, acute mixed phenotypic leukemia, acute myeloid leu... [+44]

Read more